Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease

Neurology

Volumn 66, Issue 7, 2006, Pages 1097-1099

  Hernán, Miguel A ^a   Logroscino, Giancarlo ^a   Rodríguez, Luis A García ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Department of Pharmacoepidemiology   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIPARKINSON AGENT; DICLOFENAC; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

AGED; ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PARKINSONISM; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; CASE CONTROL STUDY; COHORT ANALYSIS; FACTUAL DATABASE; GENERAL PRACTICE; SEXUAL DEVELOPMENT; TREMOR; UNITED KINGDOM;

ACETAMINOPHEN; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIPARKINSON AGENTS; ASPIRIN; CASE-CONTROL STUDIES; COHORT STUDIES; DATABASES, FACTUAL; FAMILY PRACTICE; FEMALE; GREAT BRITAIN; HUMANS; INCIDENCE; MALE; PARKINSON DISEASE; SEX CHARACTERISTICS; TREMOR;

EID: 33646089430     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000204446.82823.28     Document Type: Article

References (10)

1. Aubin N, Curet O, Deffois A, Carter C. Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J Neurochem 1998;71:1635-1642.
2. Teismann P, Ferger B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 2001;39:167-174.
3. Chen H, Zhang S, Hernán MA, et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003;60:1059-1064.
4. Jick SS, Kaye JA, Vasilakis-Scaramozza et al. Validity of the General Practice Research Database. Pharmacotherapy 2003;23:686-689.
5. Hernán MA, Logroscino G, García Rodríguez LA. A prospective study of alcoholism and the risk of Parkinson's disease. J Neurol 2004;251(suppl 7):VII/14-7.
6. Bower J, Maraganore D, McDonnell S, Rocca W. Influence of strict, intermediate, and broad diagnostic criteria on the age- and sex-specific incidence of Parkinson's disease. Mov Disord 2000;15:819-825.
7. García Rodríguez LA, Hernández-Díaz. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology 2001;12:570-576.
8. de Abajo FJ, García Rodríguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol 2001;1:1.
9. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995;310:827-830.
10. Ascherio A, Zhang SM, Hernán MA, et al. Prospective study of caffeine consumption and risk of Parkinson's disease in men and women. Ann Neurol 2001;50:56-63.